-
T Daikeler,
T Hügle,
D Farge, M Andolina,
F Gualandi,
H Baldomero,
C Bocelli-Tyndall,
M Brune,
J H Dalle,
C Urban, [......],
B Lioure,
A Marmont,
S Matthes-Martin,
D Nachbaur,
P Schuetz,
A Tyndall,
J M van Laar,
P Veys,
R Saccardi,
A Gratwohl
[show abstract]
[hide abstract]
ABSTRACT: Allogeneic hematopoietic SCT (HSCT) has been used as treatment for single patients with autoimmune diseases (AD). To summarise currently available information, we analyzed all patients who underwent allogeneic HSCT for AD and who reported to the European Group for Blood and Marrow Transplantation (EBMT) database. Thirty-five patients receiving 38 allogeneic transplantations for various hematological and non-hematological AD were identified. Four patients had had an allogeneic HSCT for a conventional hematological indication in the past. Fifty-five per cent of the transplantation procedures led to a complete clinical response of the refractory AD and 23% to at least a partial response. The median duration of response at the last follow-up was 70.7 (15.2-130) months. Three patients relapsed at a median of 12.3 months after HSCT. Treatment-related mortality at 2 years was 22.1% (95% CI: 7.3-36.9%). Two deaths were caused by progression of AD. The probability of survival at 2 years was 70%. No single factor predicting the outcome could be identified. The retrospective nature of this study and the heterogeneous, partly incomplete data are its limitations. However, allogeneic HSCT can induce remission in patients suffering from refractory AD. These data provide the basis for carefully conducted prospective trials.
Bone marrow transplantation 02/2009; 44(1):27-33. · 3.00 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The possible role of haematopoietic SCT (HSCT) for the treatment of severe autoimmune diseases was originally supported by animal experiments and remission of concomitant autoimmune diseases in patients undergoing transplantation for haematological disorders. Since 1996, over 100 procedures were performed in children with different severe autoimmune diseases such as juvenile idiopathic arthritis, systemic lupus erythematosus, systemic sclerosis, immune cytopaenias and Crohn's disease. This review tries to summarize the published data on efficacy and toxicity of HSCT in this group of patients.
Bone Marrow Transplantation 06/2008; 41 Suppl 2:S96-9. · 3.75 Impact Factor
-
R Saccardi,
T Kozak,
C Bocelli-Tyndall,
A Fassas,
A Kazis,
E Havrdova,
E Carreras,
A Saiz,
B Löwenberg,
P A W te Boekhorst, [......],
G Meucci,
R A Sáez,
R E Clark,
M N Fernandez,
L Fouillard,
B Herstenstein,
V Koza,
E Cocco,
H Baurmann,
G L Mancardi
[show abstract]
[hide abstract]
ABSTRACT: Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995-2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.
Multiple Sclerosis 01/2007; 12(6):814-23. · 4.26 Impact Factor
-
A Gratwohl,
J Passweg,
C Bocelli-Tyndall,
A Fassas,
J M van Laar,
D Farge, M Andolina,
R Arnold,
E Carreras,
J Finke, [......],
I Lisukov,
B Löwenberg,
A Marmont,
J Moore,
R Saccardi,
J A Snowden,
F van den Hoogen,
N M Wulffraat,
X W Zhao,
A Tyndall
[show abstract]
[hide abstract]
ABSTRACT: Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We have evaluated the toxicity and disease response in 473 patients with severe autoimmune disease treated with autologous HSCT between 1995 and 2003, from 110 centers participating in the European Group for Blood and Marrow Transplantation (EBMT) autoimmune disease working party database. Survival, transplant-related mortality, treatment response and disease progression were assessed. In all, 420 patients (89%; 86+/-4% at 3 years, median follow-up 20 months) were alive, 53 (11%) had died from transplant-related mortality (N=31; 7+/-3% at 3 years) or disease progression (N=22; 9+/-4% at 3 years). Of 370 patients, 299 evaluable for response (81%) showed a treatment response, which was sustained in 213 (71% of responders). Response was associated with disease (P<0.001), was better in patients who received cyclophosphamide during mobilization (relative risk (RR)3.28 (1.57-6.83)) and was worse with increasing age (>40 years, RR0.29 (0.11-0.82)). Disease progression was associated with disease (P<0.001) and conditioning intensity (high intensity, RR1; intermediate intensity, RR1.81 (0.96-3.42)); low intensity, RR2.34 (1.074-5.11)). These data from the collective EBMT experience support the hypothesis that autologous HSCT can alter disease progression in severe autoimmune disease.
Bone Marrow Transplantation 05/2005; 35(9):869-79. · 3.75 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Immune dysregulation, polyendocrinopathy and enteropathy with X-linked inheritance (IPEX) is a serious disease arising from mutations in FOXP3. This gene codifies for a transcription factor whose dysfunction results in hyperactivation of T cells. It is not clear, however, why an intermediate phenotype is not seen in heterozygous females, who are completely healthy. In order to address this question, we investigated X-chromosome inactivation in peripheral blood lymphocytes from a heterozygous female with a child affected by IPEX. No preferential inactivation was shown in freshly sorted CD4+, CD8+, CD19+ cells or in IL-2 cultured CD4 and CD8 T cells, indicating that peripheral blood lymphocytes in these women are randomly selected. Moreover, only one single FOXP3 transcript was expressed by CD4 T cell clones analysed by RT-PCR, confirming that this gene is subject to X- inactivation. We hypothesize that hyper-activation of T cell in carriers of FOXP3 mutations is regulated by the presence of normal regulatory T cells.
Clinical & Experimental Immunology 11/2002; 130(1):127-30. · 3.36 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: We describe a 10-month-old boy diagnosed with X-linked hyper-IgM syndrome (XHIM) after suffering from life-threatening acute respiratory distress syndrome (ARDS) caused by Pneumocystis carinii pneumonia (PCP), although his previous clinical history and first level laboratory tests investigating immunological function did not indicate immunodeficiency. When the patient's overall condition was good, elective bone marrow transplantation from an HLA-matched older brother was performed successfully. We describe how correct diagnosis and successful treatment were made possible thanks to the involvement of a network of specialists.
Bone Marrow Transplantation 08/2002; 30(1):49-52. · 3.75 Impact Factor
-
A Balduzzi,
M G Valsecchi,
D Silvestri,
F Locatelli,
L Manfredini,
A Busca,
A P Iori,
C Messina,
A Prete, M Andolina,
F Porta,
C Favre,
S Ceppi,
G Giorgiani,
E Lanino,
A Rovelli,
F Fagioli,
C De Fusco,
R Rondelli,
C Uderzo
[show abstract]
[hide abstract]
ABSTRACT: Hematopoietic stem cell transplantation can cure high-risk acute leukemia (AL), but the occurrence of non-leukemic death is still high. The AIEOP conducted a prospective study in order to assess incidence and relationships of early toxicity and transplant-related mortality (TRM) in a pediatric population. Between 1990 and 1997 toxicities reported in eight organs (central nervous system, heart, lungs, liver, gut, kidneys, bladder, mucosa) were classified into three grades (mild, moderate, severe) and prospectively registered for 636 consecutive children who underwent autologous (216) or allogeneic (420) transplantation, either from an HLA compatible related (294), or alternative (126) donor in 13 AIEOP transplant centers. Overall, 47% of the patients are alive in CR (3-year EFS: 45.2%, s.e.: 2.1), 19% died in CR at a median of 60 days (90-day TRM: 14.3%, s.e.: 1.4), 34% relapsed. Toxicity of any organ, but mucosa and gut, was positively correlated with early death; moderate and severe toxicity to heart, lungs, liver and kidneys significantly increased early TRM, with estimated relative risks of 9.1, 5.5, 2.7 and 2.8, respectively, as compared to absent or mild toxicity. Patients with grade III-IV aGVHD experienced more than double (56% vs. 19%) TRM than patients with grade 0-II aGVHD. A higher cumulative toxicity score, estimating the impact of toxicity on TRM, was significantly associated with transplantation from an alternative donor. Quantitative assessment allowed us to describe the extent to which 'grade' of toxicity and 'type' of involved organs were related to mortality and pre-transplant characteristics and yielded a prognostic score potentially useful to compare different conditioning regimens and predict probability of early death.
Bone Marrow Transplantation 02/2002; 29(2):93-100. · 3.75 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A mismatched bone marrow transplantation is feasible only if the donor's marrow lymphocytes are eliminated from the graft. This can be achieved by several methods, but all have the disadvantage of inducing a long-lasting immune deficiency while the risk of graft rejection and leukemic relapse increase. We use a sort of functional T-cell depletion by treating the cells with vincristine and methylprednisolone. This method is surely the cheapest and has allowed us to perform 60 transplants with a tolerable risk of GVHD. The treatment of the donor's lymphocytes has already been demonstrated to be able to block the mixed lymphocyte culture reaction in vitro. In this experiment Th1 and Th2 activities were almost completely blocked without reduction of lymphocyte viability and apoptosis induction.
Haematologica 12/2000; 85(11 Suppl):86-8. · 6.42 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: From 1986 to June 2000, sixty children suffering from acute and chronic leukemia (n = 42, 33 of which in resistant relapse), genetic diseases (n = 11), aplastic anemia (n = 2, one of which with platelet refractoriness and bleeding), myelodysplasia (n = 5) received an haploidentical bone marrow, mismatched for 2-3 HLA loci. The donor's marrow was treated in vitro with vincristine and methylprednisolone to obtain a functional T depletion (MLC and CTL inhibition, functional blockade of Th1 and Th2). The prevalence of infectious complications and GVHD was similar to that recorded in matched unrelated donor (MUD) transplants. In situations of high risk of rejection (chronic leukemia, genetic diseases) we infused immediately one half of the harvest and then frozen aliquots from the second week. Of the 25 ALL and 8 AML in resistant relapse, 3 survived, disease-free at 14, 8 and 1 years respectively. Of the 3 ALL, transplanted during remission, 1 is surviving at 18 months. Of the 6 CML, 1 had fractionated bone marrow and is surviving at 3 years, and 5 had standard single dose infusion and died of progression of their disease after rejection of the graft (4) or blast crisis after complete engraftment (1). The 2 patients with aplastic anemia, those with myelodysplasia, and 6 of the 10 with genetic disorders died of transplant-related complications or disease progression. 4 patients with osteopetrosis (n = 2), MLD (n = 1), Wiskott Aldrich dis. (n = 1) survive at 8, 2, 5 and 1.5 years respectively. In patients transplanted with fractionated marrow GVHD > 2nd grade occurred in 15%. Only one patient rejected the graft. Compared with MUD transplantation, mismatched BMT whenever performed in patients in good conditions provides similar outcome and widens the donor availability.
Haematologica 12/2000; 85(11 Suppl):37-40. · 6.42 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Forty-five consecutive patients submitted to a bone marrow transplant (BMT) were followed up weekly in order to evaluate the incidence of cytomegalovirus (CMV) infections on the basis of CMV antigenemia and polymerase chain reaction. All but one transplanted patients engrafted; fourteen patients out of these were CMV antigenemia positive after 16-184 days (median 32.5, mean 43.4) with an 31.8% incidence. CMV infections were associated with graft-versus-host disease and immunogenetic relationship between the donor and the recipient. No CMV infection was detectable in autologous transplants while antigenemia was demonstrated in 3/11 and 6/7 patients with BMT from respectively mismatched related and matched unrelated donors.
Haematologica 12/2000; 85(11 Suppl):54-7. · 6.42 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to evaluate the tolerability and effectiveness of a non-myeloablative conditioning regimen followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune diseases.
From 1996 patients with severe autoimmune disease not responsive to conventional immunosuppressive treatment were selected. The patients' blood or marrow cells were harvested after incubation with vincristine and methylprednisolone. Two different immunoablative conditioning regimens were employed. The first used cyclophosphamide (2500 mg/m2 in one day) and antilymphocyte globulin (ALG) (15 vials/m2 in three days) and the second used fludarabine (300 mg/m2 in two courses of 5 days) plus ALG (25 vials/m2 in 5 days).
Nineteen patients (14 female, 5 male) with severe autoimmune diseases were treated. Nine had a rheumatologic disorder (5 juvenile chronic arthritis, 1 rheumatoid arthritis, 1 systemic vasculitis, 1 Sjögren's syndrome, 1 Behçt's disease), 4 a neurologic disorder (3 multiple sclerosis, 1 myasthenia), 3 a haematologic disease (2 pure red cell aplasia, 1 autoimmune thrombocytopenia), 2 had a gastrointestinal disease (1 Crohn's disease, 1 autoimmune enteropathy) and 1 had a multiple autoimmune disorder. There was no regimen-related toxicity and no opportunistic infections occurred. Ninety percent of the patients improved and/or had a complete remission after the procedure. Fifty percent of the subjects went into complete or partial remission after a median follow-up of 15 months (range 3-25) while 50% relapsed after a median follow-up of 11 months, (range 6-16). The incidence of relapse in the group treated with fludarabine was lower (30%).
A non-myeloablative conditioning regimen was able to induce persistent remission in some patients with severe autoimmune diseases. There was no mortality or morbidity related to the procedure. The extent of remission does, however, remain to be established.
Haematologica 12/2000; 85(11 Suppl):81-5. · 6.42 Impact Factor
-
Bone Marrow Transplantation 11/2000; 26(8):929. · 3.75 Impact Factor
-
C Messina,
S Cesaro,
R Rondelli,
F Rossetti,
F Locatelli,
A Pession,
R Miniero,
G Dini,
C Uderzo,
S Dallorso, [......],
C Favre,
G Basso,
G Sotti,
S Varotto,
R Destro,
M V Gazzola,
M Pillon,
M G Petris,
M Rabusin,
G Scarzello
[show abstract]
[hide abstract]
ABSTRACT: From January 1984 to December 1994, ABMT was performed on 154 children (101 males, 53 females; median age 10, range 3-21 years) with ALL and registered for BMT by the AIEOP (Italian Association of Paediatric Haemato-Oncology). All patients were in CR: 98 were in 2nd CR and 56 were in >2nd CR. Fifteen children (9.7%) died of transplant-related mortality. Ninety-five patients (61.6%) relapsed at a median of 5 (range 1-42) months after ABMT. The 8-year EFS according to pre-BMT status was 34.6% (s.e. 4.9) for 2nd CR patients and 10.6% (s.e. 5.6) for patients in >2nd CR. By univariate analysis, site of relapse (isolated extramedullary (IE) vs BM: EFS = 68.5% vs 18.2%; P < 0.0001) and TBI containing regimen (TBI vs no TBI: EFS = 48.1 vs 15.4%; P = 0.0023) were significant factors for 2nd CR patients. When the 2nd CR subset with BM involvement was analysed, TBI became insignificant (EFS = 25.4 vs 11.8%). No factors influenced EFS in patients in >2nd CR. By multivariate analysis, site of relapse was the only significant factor in 2nd CR patients (P < 0.0001). In conclusion, ABMT is an effective treatment after one early IE relapse. Few patients can be rescued after BM relapse.
Bone Marrow Transplantation 05/1998; 21(10):1015-21. · 3.75 Impact Factor
-
The International journal of artificial organs 02/1998; 21(1):63-4. · 1.86 Impact Factor
-
C Uderzo,
M G Valsecchi,
A Balduzzi,
G Dini,
R Miniero,
F Locatelli,
R Rondelli,
A Pession,
W Arcese,
A Bacigalupo,
P Polchi, M Andolina,
C Messina,
V Conter,
M Aricó,
S Galimberti,
G Masera
[show abstract]
[hide abstract]
ABSTRACT: We compared the outcome of children with high-risk acute lymphoblastic leukaemia (HR-ALL) in first complete remission (first CR) treated with chemotherapy (CHEMO) or with allogeneic bone marrow transplantation (BMT) in a multicentre study. All children treated by the Italian Paediatric Haematology Oncology Association for HR-ALL in first CR between 1986 and 1994 were eligible for the study. 30 children were given BMT at a median of 4 months from first CR, with preparative regimens including total-body irradiation (n = 25/30). 130 matched controls for BMT patients were identified among 397 HR-ALL CHEMO patients. Matching on main prognostic factors and duration of first CR was adopted to control the selection and time-to-transplant biases. The comparative analysis was based on the results of a stratified Cox model. The estimated hazard ratios of BMT versus CHEMO at 6 months, 1 year and 2 years after CR were 1.38 (CI 0.59-3.24), 0.69 (CI 0.27-1.77) and 0.35 (CI 0.06-1.91), with an overall non-significant difference between the two groups (P = 0.34). With a median follow-up of 4 years, the disease-free survival was 58.5% (SE 9.3) in the BMT group and 47.7% (SE 4.8) in the CHEMO group, at 4 years from CR. Non-leukaemic death occurred in 4% of CHEMO and 10% of BMT patients. In the BMT group the estimated cumulative incidence of relapse at 1.5 years from CR was 31.5% (SE 8.8) and did not change thereafter, whereas in the CHEMO group the corresponding figure was 29.2% (SE 4.1) and the incidence continued to increase thereafter (48.2% (SE 4.8) at 4 years from CR). The results of this study suggest that, with respect to the CHEMO group, the higher risk of early failure in the BMT group is outweighed by the lower risk of relapse after 1 year. Results prompt the need for a prospective study, in order to demonstrate the likely advantage of BMT in HR childhood ALL in first CR.
British Journal of Haematology 03/1997; 96(2):387-94. · 4.94 Impact Factor
-
C Uderzo,
M G Valsecchi,
A Balduzzi,
A Rovelli,
G Dini,
R Miniero,
F Locatelli,
R Rondelli,
W Arcese, M Andolina,
C Messina,
P Polchi,
E Biagi,
C Arrigo,
D Silvestri,
G Masera,
A Bacigalupo
Bone Marrow Transplantation 12/1996; 18 Suppl 2:25-7. · 3.75 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The same ex vivo marrow's treatment that we used in mismatched BMT (incubation with vincristine and methylprednisolone) was used in two patients with chronic GVHD and in one patient with PRCA. The conditioning regimen with cyclophosphamide and ALG was aimed to kill only the patient's lymphocytes, and did not cause a deep myeloid aplasia. The patients achieved a clear improvement of their symptoms.
Bone Marrow Transplantation 12/1996; 18 Suppl 2:145-7. · 3.75 Impact Factor
-
A Garaventa,
R Rondelli,
E Castagnola,
F Locatelli,
S Dallorso,
F Porta,
C Uderzo,
F Rossetti,
R Miniero, M Andolina,
A Amici,
A P Iori,
P Di Bartolomeo,
G Dini,
A Pession,
P Paolucci,
C Viscoli
Bone Marrow Transplantation 12/1996; 18 Suppl 2:160-2. · 3.75 Impact Factor
-
R Miniero,
A Busca,
S Vai,
F Locatelli,
F Porta,
C Messina,
G Dini,
W Arcese,
A Amici, M Andolina,
C Uderzo,
P Di Bartolomeo,
P Paolucci,
A Pession
Bone Marrow Transplantation 12/1996; 18 Suppl 2:135-8. · 3.75 Impact Factor
-
C Messina,
R Rondelli,
M G Valsecchi,
F Rossetti,
R Miniero,
G Meloni,
F Locatelli,
M Aricò,
A M Testi,
G Dini, [......],
N Santoro,
B Werner,
G De Rossi,
G Loiacono, M Andolina,
A Lippi,
C Favre,
A Amici,
M Lo Curto,
G Masera
[show abstract]
[hide abstract]
ABSTRACT: The role of autologous bone marrow transplantation (ABMT) in childhood ALL after an isolated extramedullary (IE) relapse is controversial. Between December 1984 and November 1995, 52 children underwent ABMT because of an IE relapse. The data were stored in the AIEOP-BMT Registry. Thirty four children were transplanted in 2nd CR; eighteen > 2nd CR. The median duration of 1st CR was 24 (range 3-69) and 18 (range 3-59) months, respectively. The median interval from last CR to ABMT was 6 (range 1-28) and 3 (range 1-81) months, respectively. The 5 year EFS for patients transplanted in 2nd CR was 67.7%, while the 3 year EFS for patients in > 2nd CR was 16.7%. In conclusion, ABMT was an effective treatment in early IE relapse only if performed in 2nd CR.
Bone Marrow Transplantation 11/1996; 18 Suppl 2:40-2. · 3.75 Impact Factor
